Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,270.00
(
0.57%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
101.44
(
0.78%
)
Bitcoin
72,954.61
(
-1.34%
)
News Focus
News Focus

Replies to post #87560 on Biotech Values

Replies to #87560 on Biotech Values
icon url

mcbio

12/15/09 7:19 PM

#87567 RE: tony111 #87560

Re: GILD/ACHN

BTW why did GILD drop their partnership with Achillion?

The GILD/ACHN partnership was not for ACH-1625, but was for ACH-1095, an NS4A antagonist (separate drug and separate HCV drug class), and ended due to GILD's concerns with pre-clinical cardiac tox signals. ACHN hopes to take ACH-1095 into Phase 1 on its own early next year; if that initial data is good, GILD has an option to opt back into the program.
icon url

DewDiligence

12/15/09 8:36 PM

#87573 RE: tony111 #87560

why did GILD drop their partnership with Achillion?

As mcbio noted, the GILD-ACHN partnership for ACH-1095 (not to be confused with ACH-1625, the drug in the news today) was restructured, not dropped. A relevant piece of background info is that ACH-1095 is a second-generation version of ACH-806, which was discontinued in 2007 due to elevations of creatinine (#msg-18754183).